The Kutcher Adolescent Depression Scale: Assessment of its evaluative properties over the course of an 8-week pediatric pharmacotherapy trial
The Kutcher Adolescent Depression Scale: Assessment of its evaluative properties over the course of an 8-week pediatric pharmacotherapy trial
复制标题
DOI：
10.1089/104454603322572679
复制
发表时间：
2003-09-01
影响因子：
1.9
通讯作者：
Kutcher, S
中科院分区：
文献类型：
--
作者：
Brooks, SJ;Krulewicz, SP;Kutcher, S
目的：自我报告工具通常用于评估抑郁症的青少年在这个年龄组有有限的或未知的心理测量特性。我们报告的库彻青少年抑郁量表（KADS），自我报告量表专门用于识别抑郁的青少年和监测症状的严重程度随时间推移，方法：一百零六名青少年与抑郁症（MDD）参加了为期8周的，双盲，安慰剂对照研究帕罗西汀的评价属性。在第0天（基线）、第7天、第14天、第21天、第28天、第42天和第56天使用自评KADS和临床医生评定的儿童抑郁评定量表-修订版（CDRS-R）、严重程度的临床总体印象（CGI）和功能总体评估（GAF）量表进行疗效评估。最初对数据进行了检查，以确定16个KADS项目中哪些对变化最敏感。随后的分析比较了三个版本的KADS的评价属性：全长KADS，一个六项子量表先前建立的筛选工具，和一个11项子量表优化的敏感性变化。结果：受试者的KADS评分和他们的临床医生评定量表评分之间的受试者内相关性表明，11项KADS评分显著更好地证实了临床医生评定的严重程度变化（与CDRS-R、CGI和GAF的平均相关性：分别为r = 0.69、0.60和-0.70），而不是六项KADS（分别为r = 0.62、0.56和-0.63），并且至少与全长KADS（分别为r = 0.64、0.56和-0.67）一样好。此外，就从第0天到第56天评分的平均百分比变化而言，11项KADS（59%）显著优于全长KADS（46%）和所有三种临床医生评定量表（分别为43%、37%和29%）并且至少与六项KADS的表现相匹配（56%）。这些结果表明，11项自评KADS是诊断为MDD的青少年治疗结果的敏感措施。
Objective: Self-report instruments commonly used to assess depression in adolescents have limited or unknown psychometric properties in this age group. We report the evaluative properties of the Kutcher Adolescent Depression Scale (KADS), a self-report scale designed specifically for identifying depressed adolescents and for monitoring symptom severity over time.Methods: One hundred and six adolescents with major depression disorder (MDD) enrolled in an 8-week, double-blind, placebo-controlled study of paroxetine. Efficacy assessments were conducted on days 0 (baseline), 7, 14, 21, 28, 42, and 56 using the self-rated KADS and the clinician-rated Children's Depression Rating Scale-Revised (CDRS-R), Clinical Global Impression (CGI) of severity, and Global Assessment of Functioning (GAF) scale. The data were initially examined to establish which of the 16 KADS items showed greatest sensitivity to change. Subsequent analyses then compared the evaluative properties of three versions of the KADS: the full-length KADS, a six-item subscale previously established as a screening tool, and an 11-item subscale optimized for sensitivity to change.Results: Within-subject correlations among subjects' KADS scores and their clinician-rated scale scores showed that clinician-rated changes in severity were significantly better corroborated by the 11-item KADS (mean correlations with the CDRS-R, CGI, and GAF: r = 0.69, 0.60, and -0.70, respectively) than by the six-item KADS (r = 0.62, 0.56, and -0.63, respectively) and at least as well corroborated as by the full-length KADS (r = 0.64, 0.56, and -0.67, respectively). Furthermore, in terms of mean percentage change in scores from day 0 to day 56, the 11-item KADS (59%) significantly outperformed the full-length KADS (46%) and all three clinician-rated scales (43%, 37%, and 29%, respectively) and at least matched the performance of the six-item KADS (56%).Conclusions: These results suggest that the 11-item self-rated KADS is a sensitive measure of treatment outcome in adolescents diagnosed with MDD.